Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin use in congestive heart failure. Current status

K Riaz1, A D Forker

  • 1Department of Internal Medicine, University Missouri-Kansas City, School of Medicine, USA.

Drugs
|June 9, 1998
PubMed
Summary

Digoxin helps manage mild heart failure by preventing clinical decline and hospitalizations, improving exercise capacity, and enhancing heart function, without impacting survival rates. This digitalis medication offers benefits even at lower doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diabetic keratopathy: Insights and challenges.

Survey of ophthalmology·2020
Same author

First Report of Dickeya dianthicola Causing Blackleg Disease on Potato Plants in Pakistan.

Plant disease·2018
Same author

Metagenomics revealed a quorum quenching lactonase QlcA from yet unculturable soil bacteria.

Communications in agricultural and applied biological sciences·2009
Same author

A cardiologist's perspective on evolving concepts in the management of congestive heart failure.

Journal of clinical pharmacology·1996
Same author

The lost art of physical diagnosis.

Hospital practice (Office ed.)·1994
Same author

Adjunctive medical therapy for acute myocardial infarction.

Postgraduate medicine·1994

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The efficacy of digitalis (digoxin) in treating congestive heart failure (CHF) with normal sinus rhythm remains a subject of ongoing debate.
  • Historical studies provided limited, often uncontrolled data, hindering definitive conclusions on digoxin's benefits and risks.

Purpose of the Study:

  • To critically evaluate the evidence for digoxin's use in heart failure, focusing on clinical outcomes, survival, and specific patient subgroups.
  • To assess the impact of digoxin on exercise tolerance, left ventricular function, and neurohormonal effects in heart failure patients.

Main Methods:

  • Review of historical uncontrolled studies (1969-1983) and higher-quality randomized, double-blind, placebo-controlled trials (1977-1991).
  • Analysis of major trials including the Prospective Randomised Study of Ventricular Failure and Efficacy of Digoxin (PROVED), Randomised Assessment of Digoxin on Inhibitors of the Angiotensin-Converting Enzyme (RADIANCE), and the Digitalis Investigation Group (DIG) trial.
  • Inclusion of a DIG trial substudy examining digoxin's effect on survival in patients with preserved ejection fraction (diastolic dysfunction).

Main Results:

  • Digoxin was shown to prevent clinical deterioration and reduce hospitalizations in heart failure patients.
  • The drug improves exercise tolerance and left ventricular function.
  • Crucially, digoxin demonstrated no adverse effect on survival rates, even in patients with ejection fraction > 45% (diastolic dysfunction).
  • Evidence suggests a potential neurohormonal effect of digoxin, possibly at doses lower than 0.25 mg, particularly benefiting patients with mild heart failure.

Conclusions:

  • Digoxin is the first inotropic agent demonstrated to improve heart failure outcomes without negatively impacting survival.
  • The drug is beneficial for patients with mild heart failure and diastolic dysfunction.
  • Further research into lower-dose digoxin and its neurohormonal mechanisms is warranted.

Related Experiment Videos